Your session is about to expire
← Back to Search
XEN Gel Stent vs Traditional Filtering Surgery for Glaucoma (Topo-XEN Trial)
Topo-XEN Trial Summary
This trial will compare the amount of postoperative corneal astigmatism induced by the XEN Gel Stent to that induced by traditional filtering surgery.
Topo-XEN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTopo-XEN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Topo-XEN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am having surgery that includes removing a cataract.I am 18 years old or older.I am under 18 years old.I have severe dry eye disease.I have eye conditions other than glaucoma, like issues with my cornea or retina.My eye pressure is too high or getting worse despite using all possible treatments.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: XEN Gel Stent implantation
- Group 2: Trabeculectomy
- Group 3: GDD implantation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What is the cap on total enrollees in this clinical research?
"Yes, the clinicaltrials.gov database reveals that this medical trial is presently recruiting individuals in need of a potential solution to their condition. The study was initially posted on November 4th 2020 and subsequently updated on May 30th 2022. A total of 90 patients must be enrolled across one location for the experiment to proceed."
Are there vacated positions available in this clinical research project?
"Yes, the clinical trial is still open for enrollment according to information hosted on clinicialtrials.gov. The study was originally launched in November 4th 2020 and its data has been refreshed as recently as May 30th 2022."
What is the key purpose of this clinical research?
"This medical trial, assessed across Baseline, 2 months, 6 months and 12 month time frames aims to measure Keratometric values using a Pentacam. Secondary outcomes include an evaluation of Ganglion cell layer (GCL+) thickness captured through Spectral Domain Optical Coherence Tomography (SD-OCT), Intraocular pressure control via Goldmann applanation tonometry and Visual field change evaluated by automated Humphrey 24-2 perimetry assessment."
Share this study with friends
Copy Link
Messenger